# **Special Issue**

# Understanding the Molecular Basis and Immunobiology of Renal Cell Carcinoma and Exploring Novel Therapeutic Strategies

## Message from the Guest Editor

Renal cell carcinoma (RCC) is the most common adult kidney tumor, characterized by its aggressiveness and unpredictable prognosis. Targeted therapies have notably improved outcomes for metastatic renal cell carcinoma (mRCC) patients. A deeper understanding of its molecular and immunobiological basis may lead to new therapeutic strategies for RCC. We are pleased to announce our Special Issue, entitled "Understanding the Molecular Basis and Immunobiology of Renal Cell Carcinoma and Exploring Novel Therapeutic Strategies", and invite you to contribute to it. In this Special Issue, original research articles and reviews are welcome to be submitted. Research areas may include, but are not limited to, the following:

- Molecular basis and immunobiology of renal cell carcinoma
- Biomarker discovery, including diagnostic, prognostic, and predictive biomarkers
- Recent advances in RCC diagnosis
- Molecular diagnostics
- Innovative therapeutic options for RCC

We look forward to receiving your contributions.

#### **Guest Editor**

Dr. Heba Khella

- 1. Department of Clinical Diagnosis and Clinical Education, Canadian Memorial Chiropractic College, Toronto, ON M2H 3J1, Canada
- 2. Department of Anatomy, Canadian Memorial Chiropractic College, Toronto, ON M2H 3J1, Canada
- 3. Department of Pathology/Microbiology, Canadian Memorial Chiropractic College, Toronto, ON M2H 3J1, Canada

### Deadline for manuscript submissions

30 June 2026



# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/215882

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

